<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02861963</url>
  </required_header>
  <id_info>
    <org_study_id>FAVVC</org_study_id>
    <nct_id>NCT02861963</nct_id>
  </id_info>
  <brief_title>Choice of Palliative Procedures for Pulmonary Atresia With Ventricular Septal Defect Patients</brief_title>
  <official_title>Femoral Allogenic Vein Valved Conduit for Palliative Repair of Pulmonary Atresia With Ventricular Septal Defect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare effective growth true hypoplastic pulmonary arteries using Right
      Ventricle Outflow Tract Reconstruction by femoral allogenic vein valve conduit and
      systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt or central shunts)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of femoral allogenic vein valve conduit for Right Ventricle Outflow Tract
      Reconstruction is good alternative systemic-to-pulmonary artery shunts (modified
      Blalock-Taussig shunt or central shunts). Main advantages is straight, symmetrical,
      pulsating, systolic blood flow in hypoplastic pulmonary artery, which stimulate growth and
      prepares for a radical repair. Taking into account the absence randomized studies in this
      area of medicine, providing investigation evaluating parameters of safety for both methodics
      is very actual.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2016</start_date>
  <completion_date type="Anticipated">March 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth of pulmonary arteries</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>-Index Nakata â‰¥ 150 mm/m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of further re interventions</measure>
    <time_frame>1 year</time_frame>
    <description>catheterization
balloon plastic of the pulmonary arteries with stenting
unification procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 year</time_frame>
    <description>pulmonary arteries stenosis
Thrombosis
Bleeding
Death
Vein graft dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pulmonary Atresia With Ventricular Septal Defect</condition>
  <condition>Tetralogy of Fallot With Pulmonary Atresia</condition>
  <arm_group>
    <arm_group_label>Right ventricle outflow tract reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic-to-pulmonary artery shunts</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt or central shunts)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Experimental: RVOT reconstruction by femoral allogenic vein valve conduit</intervention_name>
    <description>Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation</description>
    <arm_group_label>Right ventricle outflow tract reconstruction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic-to-pulmonary artery shunts</intervention_name>
    <description>Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type &quot;end to side&quot;. Central Shunt performed between ascending part of aorta and main pulmonary artery.</description>
    <arm_group_label>Systemic-to-pulmonary artery shunts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With concordant atrio - ventricular concordant, and ventriculo - arterial connection

          -  A and B type by Tchervenkov

          -  Open palliative interventions MBTS or RVOT reconstruction without VSD closure using
             allogenic valve vein conduit

        Exclusion Criteria:

          -  With disconcordant of atrio - ventricular and discordant, ventriculo - arterial
             connection

          -  C type byTchervenkov

          -  Other surgical interventions (primary complete repair, endovascular treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Y Omelchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meshalkin Research Institute of Pathology of Circulation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexey Voitov, MD</last_name>
    <phone>89231444787</phone>
    <email>alex99.88@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novosibirsk State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Voitov</last_name>
      <phone>89231444787</phone>
      <email>alex99.88@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Alexey V Voitov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Y Omelchenko, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(13)02368-0</url>
    <description>Growth of diminutive central pulmonary arteries after right ventricle to pulmonary artery homograft implantation</description>
  </link>
  <link>
    <url>https://academic.oup.com/icvts/article-lookup/doi/10.1093/icvts/ivu052</url>
    <description>Establishment of right ventricle-pulmonary artery continuity as the first-stage palliation in older infants with pulmonary atresia with ventricular septal defect may be preferable to use of an arterial shunt.</description>
  </link>
  <link>
    <url>http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(11)01410-X</url>
    <description>Side-to-side aorto-GoreTex central shunt warrants central shunt patency and pulmonary arteries growth.</description>
  </link>
  <link>
    <url>http://linkinghub.elsevier.com/retrieve/pii/S0003-4975(97)01126-0</url>
    <description>Side-to-side aorto-Gore-Tex central shunt</description>
  </link>
  <results_reference>
    <citation>Hibino N, He D, Yuan F, Yu JH, Jonas R. Growth of diminutive central pulmonary arteries after right ventricle to pulmonary artery homograft implantation. Ann Thorac Surg. 2014 Jun;97(6):2129-33. doi: 10.1016/j.athoracsur.2013.10.046. Epub 2014 Jan 10.</citation>
    <PMID>24418205</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng S, Yang K, Li K, Li S. Establishment of right ventricle-pulmonary artery continuity as the first-stage palliation in older infants with pulmonary atresia with ventricular septal defect may be preferable to use of an arterial shunt. Interact Cardiovasc Thorac Surg. 2014 Jul;19(1):88-94. doi: 10.1093/icvts/ivu052. Epub 2014 Mar 30.</citation>
    <PMID>24686154</PMID>
  </results_reference>
  <results_reference>
    <citation>Barozzi L, Brizard CP, Galati JC, Konstantinov IE, Bohuta L, d'Udekem Y. Side-to-side aorto-GoreTex central shunt warrants central shunt patency and pulmonary arteries growth. Ann Thorac Surg. 2011 Oct;92(4):1476-82. doi: 10.1016/j.athoracsur.2011.05.105.</citation>
    <PMID>21958799</PMID>
  </results_reference>
  <results_reference>
    <citation>Gates RN, Laks H, Johnson K. Side-to-side aorto-Gore-Tex central shunt. Ann Thorac Surg. 1998 Feb;65(2):515-6.</citation>
    <PMID>9485256</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2016</study_first_submitted>
  <study_first_submitted_qc>August 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meshalkin Research Institute of Pathology of Circulation</investigator_affiliation>
    <investigator_full_name>Alexey Voitov</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Femoral Allogenic Vein Valve Conduit</keyword>
  <keyword>Rehabilitation of native pulmonary arteries</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Heart Septal Defects, Ventricular</mesh_term>
    <mesh_term>Pulmonary Atresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

